Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Aug 4;19:90. doi: 10.1186/s13058-017-0882-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 3 — The effect of gefitinib-FTY720 treatment on CD44 expression in TNBC cell lines. HCC1806, Hs578T, and MDA-MB-468 TNBC cell lines at ~40% confluence in 12-well plates were exposed for 24 h to gefitinib (Gef: 0.1 to 10 μM), with or without the addition of 1.5 μM FTY720, as indicated. Upper panels: detection of standard isoform (~80 kDa) CD44 in cell lysates by western blotting. α-Tubulin (α-tub) is shown as a loading control. Lower panels: quantitation of the ~80-kDa band density was normalized to band density for cells receiving 0 gefitinib. Bars are mean value ± SEM for six (HCC1806), six (Hs578T) or three (MDA-MB-468) replicate samples. P values indicate significance of the effect of FTY720 addition, calculated over the three gefitinib doses by repeated measures ANOVA